You can get peptides from a pharmacy on prescription, from a 503A compounding pharmacy, or from the research-chemical market. Those are the three routes, and the answer to where to get peptides depends entirely on which compound you want. For most of the popular ones, only the third route is open.
The short version
Peptides come from three routes, and the compound you are after decides which one is open to you. Prescription covers the few peptides approved as drugs, while 503A compounding covers approved active ingredients. The research-chemical market covers everything else, which is most of what people search for on this site.
Peptides don't share one answer. Tesamorelin and BPC-157 come from different places, and the difference isn't about the seller. It's about whether the molecule has ever been through an approval.
Where can you get peptides?
You have three places to get peptides, and they aren't interchangeable. Here's each one, and what it actually hands you.
- A retail pharmacy, on prescription. Open only for peptides approved as drugs: semaglutide, tirzepatide, tesamorelin, PT-141. You get a GMP product with sterility assurance and a regulator behind it.
- A 503A compounding pharmacy. Open for approved active ingredients, prepared per patient on a prescription. You get pharmacy oversight and a contested regulatory history.
- The research-chemical market. Open for everything else, which is most of this library. You get lyophilized powder, research-use-only labeling, and whatever testing the seller chose to pay for.
| Route | What it covers | What you get |
|---|---|---|
| Prescription | Peptides approved as drugs — semaglutide, tirzepatide, tesamorelin, PT-141 | GMP product, sterility assurance, clinical oversight, a regulator behind it |
| 503A compounding | Approved active ingredients, prepared per-patient | Pharmacy-prepared, oversight, but a contested regulatory history |
| Research chemicals | Everything else — BPC-157, retatrutide, the bioregulators, most of this library | Lyophilized powder, research-use-only labeling, whatever testing the seller chose to do |
Which route applies to your compound?
Peptides sort themselves by one test: does the compound have a brand name? If it does, a prescription route exists. If it doesn't, there's nothing for a prescriber to write.
Tesamorelin is Egrifta. Semaglutide is Wegovy and Ozempic. Tirzepatide is Zepbound and Mounjaro. PT-141 is Vyleesi. Those four you can get at a pharmacy.
Everything without a brand name has no prescription route at all. That covers BPC-157, TB-500, epithalon, the Khavinson bioregulators, and retatrutide while it stays in Phase 3.
The route changes the product, not just the paperwork. Prescription semaglutide and research semaglutide can be the same molecule without being the same thing.
What differs is sterile fill-finish, endotoxin testing, batch release, stability programs, and somebody empowered to force a recall. We'd say those controls are most of what the prescription price buys you.
Who sells on the research route?
Most people reading this land on the third route, so here are six suppliers on it by name, with the price and the certificate checked on their own storefronts on 13 August 2026. Prices are benchmarked on BPC-157, the most widely stocked compound in this market, so the rows compare against each other. Disclosure: Where To Buy Peptides earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to — every cell below is a document you can open or a price you can load for yourself.
| Route | What it covers | What you need | Where it fails |
|---|---|---|---|
| Pharmacy, on prescription | Approved drugs only — semaglutide, tirzepatide, PT-141 as Vyleesi, tesamorelin as Egrifta | A prescription and a diagnosis that fits the label | Covers almost nothing in this catalogue. Most research peptides have no approved product |
| 503A compounding pharmacy | Substances on the FDA bulks list, prepared to a prescription | A prescriber willing to order it | BPC-157, KPV, TB-500 and MOTS-c were only reviewed for the list in July 2026; an advisory vote is not rulemaking |
| Research-supply vendor | Everything else, sold as research-use-only material | Nothing. It ships to any US state by mail | Unregulated on quality. Which vendor you pick is the whole decision, so check the certificate before the price |
† Peptriva and Red Rock sell BPC-157 in a 10 mg vial only, so their sticker prices are not like-for-like against a 5 mg row — per milligram they work out at $6.30 and $6.90. ‡ Swiss Chems sells the arginine salt of BPC-157 rather than the plain peptide, and the sale price is shown; its list price is $49.99. Red Rock is the floor of the set rather than a recommendation: it advertises “Verified With COAs” and publishes none at all. The full ten-vendor comparison adds domain age, and the four suppliers other lists still recommend that you cannot buy from today.
The pattern worth taking from that table is that price and documentation move independently. The cheapest per-milligram row and the row with no certificate at all are within $0.60/mg of each other, so a low price tells you nothing on its own about what is in the vial.
Research compounds
For the compounds with no prescription route, this is the research-chemical market — supplied with a batch-matched third-party certificate of analysis for the lot you receive.
How do you check a research-chemical supplier?
On the research route for peptides, the seller is the only quality control in the chain. So the question becomes how you check the seller. One email does most of the work: ask for the certificate of analysis for the lot they'd actually ship you.
What comes back sorts the market faster than any review site. Four things to look for.
- A CoA matched to a lot number, not a specimen report from whenever they last tested.
- A named third-party lab, ISO 17025-accredited, rather than internal QC.
- A mass-spec identity line, not just an HPLC purity percentage.
- A straight answer, quickly. A supplier who stalls on this one question will stall on the ones that matter more.
“
Distribution of in vitro diagnostic products labeled for research use only or investigational use only.
— FDA guidance, 2013. The document the entire research-chemical market rests on.
Our per-compound sourcing guides cover identity checks, fair pricing and the specific ways each peptide gets substituted. They're all in the A–Z index.
Frequently asked questions
Where do you get peptides?
Three routes exist, and they aren't equivalent. A prescription covers the handful of peptides approved as drugs. A 503A compounding pharmacy covers approved active ingredients. The research-chemical market covers everything else. Which one applies depends entirely on the compound.
Can you get peptides without a prescription?
Research-use-only material, yes — that is the whole basis of the research-chemical market. Approved drugs like tesamorelin (Egrifta) or semaglutide (Wegovy), no. The compound decides, not the seller.
Can you get peptides at a pharmacy?
Only the ones approved as drugs, and only with a prescription. A pharmacy cannot dispense BPC-157 or retatrutide because neither is an approved product.
Do peptide clinics work?
Telehealth and wellness clinics prescribe approved or compounded peptides with clinical oversight attached, which is a genuine advantage. What they cannot do is supply compounds that have no approved active ingredient behind them.
How long does it take to get peptides?
Domestic research suppliers generally ship in days. International orders are the common failure point — customs treats unapproved drug material unpredictably, and a seized shipment is not usually refunded.
Research compounds
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- Three routes exist: prescription, 503A compounding, and the research-chemical market, and the compound decides which is open.
- Prescription covers only the small number of peptides that have been approved as drugs.
- A 503A compounding pharmacy can work only from approved active ingredients, which excludes most research compounds.
- Most peptides people search for fall outside both routes, leaving only research-use-only material.
- The research route is the least protected of the three, and it is where most searches end up.
“
Once-weekly semaglutide in adults with overweight or obesity.
— Wilding et al., NEJM, 2021. The trial that made the prescription route worth wanting.
What we’re watching
The route map for peptides moves whenever a compound crosses an approval line. Retatrutide is the next one likely to do it, and approval would open both the pharmacy and the compounding routes overnight.
We're also watching the FDA's 503A bulk drug substance lists. Those lists decide which peptides a compounding pharmacy may touch at all, and they have been contested since 2023.
References
- U.S. Food and Drug Administration. (2013). Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038